The SpaceX IPO is structured to give Elon Musk unprecedented and permanent control, with special voting shares that make him impossible to remove. This is presented as a significant departure from even other founder-led tech companies, raising major concerns about shareholder rights and corporate oversight.
The core investment thesis for SpaceX is positioned not just as a rocket or satellite company, but as a long-term play on the future of AI. The vision is to use its launch capabilities and Starlink constellation to build and operate AI-powered data centers in space, which is seen as the optimal delivery mechanism for future AI services.
Medical device companies like Medtronic are demonstrating strong performance in specific high-growth areas like Pulse Field Ablation. However, the industry faces a recurring threat from the rise of GLP-1 drugs, now in oral form, which could potentially reduce the long-term volume of medical procedures.
Bloomingdale's is successfully executing a strategy to move further upmarket by adding luxury boutiques like Chanel and Prada. This is driving double-digit sales growth and allowing it to take significant market share from distressed competitors like Saks Fifth Avenue and Neiman Marcus.
Despite possessing a pipeline of promising and disruptive technologies, Medtronic has a history of inconsistent execution. This reputation makes investors cautious, as the company has often failed to fully capitalize on its innovations, leading to revised guidance and retracing momentum.
Keep pulling the thread on Bloomberg Intelligence.